Home Tags Biological License Application

Tag: Biological License Application

Food and Drug Administration Issues Complete Response Letter for Byondis’ [Vic-]Trastuzumab...

ADC Review | Editorial Team
Earlier this week, the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) for Byondis' Biological License Application (BLA) for the company's anti-HER2 antibody-drug conjugates [vic-] trastuzumab duocarmazine, also known as SYD985.
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X